History | SapiensBio Sapiensbio skip to Main Content


Data-Driven Technology-Based Drug Discovery Solution


Making a better world with innovative data-driven drug discovery and development


Growth Stage

  • Attended the JPM Healthcare Conference 2024


Growth Stage

  • Selected as a Presenting Company in BioTech Showcase 2023
  • Selected as a Presenting Company in Bio CEO & Investor 2023
  • Attended the Bio Europe, Spring 2023
  • Selected as a Presenting Company in Asia Bio Partnering Forum 2023
  • 9 valuable meetings regarding L/O of SBC101 in Bio Korea 2023
  • Attended the Bio International Convention 2023
  • Selected as the operating company for the Third National New Drug Development Project in 2023


Growth Stage

  • Selected as a Presenting Company in Bio Europe 2022
  • Attended Bio USA 2022
  • 2 Patents submitted: Composition of matter
  • Signed a joint R&D agreement with ADDI in UK
  • Launched an innovative machine learning & wet lab workflow drug discovery platform, Sapientia
  • Changed the Corporate Name to SapiensBio, Inc.


Research and Evaluation Stage

  • Novel Target Identification & Validation
  • Implementation of an in-house wet lab experimentation system
  • Patent submitted: Composition of matter
  • Participated in Bio USA 2021
  • Started fibrosis & Alzheimer’s disease treatment
  • Changed the name from Ailon to SapiensBio, Inc

2019 ~ 2020

Development stage

  • Obtained Venture Business and Corporate R&D Institute Certifications
  • Invented new AI drug discovery platform, Sapientia


Foundation stage

  • Establishment of Ailon, Inc.
Back To Top